ReviewAnnals of medicine2026
Preclinical advances and mechanistic insights of CAR-T therapy for acute myeloid leukemia: from target iteration to microenvironment regulation.
Review in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advances in Oncohematology Immunotherapy: Monoclonal Antibodies and CAR T-Cell Therapies.Cells · 2026Review
- Advancements in diagnosis and treatments of acute leukemia.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRelapsed/refractory acute myeloid leukaemia (AML) carries a dismal prognosis, primarily due to profound biological heterogeneity and the scarcity of effective targeted therapies. Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a transformative investigational strategy for AML by genetically engineering T cells to specifically target tumour antigens; however, its clinical translation is severely impeded by target antigen scarcity and the immunosuppressive tumour microenvironment (TME). DISCUSSION: This review systematically summarizes the preclinical advances and mechanistic underpinnings of CAR-T therapy for AML, focusing on two core bottlenecks. First, it elaborates on the screening of candidate antigens (e.g. CD33, CD123) and cutting-edge target optimization strategies, including nanobody-based CARs, logic-gated systems, adapter-CAR technology and combinatorial approaches to mitigate antigen escape. Second, it dissects the inhibitory effects of the AML TME on CAR-T function and reviews corresponding intervention tactics, such as immune checkpoint blockade, cytokine arming and gene editing. Integrating key updates from the 2024 ASH Annual Meeting, the review also highlights emerging preclinical technologies, including off-the-shelf CAR-T, CAR-NK cells and γδ T cell therapy. Importantly, it acknowledges the prevalent preclinical-to-clinical translation gap, where promising lab efficacy has not yet translated into consistent clinical success.
conclusionsMultidimensional technological innovation and the synergistic optimization of combination therapies are critical to overcoming AML-specific barriers. These advances hold the potential to unlock the precise clinical application of CAR-T therapy, ultimately improving survival outcomes for patients with relapsed/refractory AML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.